Early efficacy evaluation of mesenchymal stromal cells (MSC) combined to biomaterials to treat long bone non-unions.


Journal

Injury
ISSN: 1879-0267
Titre abrégé: Injury
Pays: Netherlands
ID NLM: 0226040

Informations de publication

Date de publication:
Apr 2020
Historique:
received: 03 12 2019
revised: 08 02 2020
accepted: 15 02 2020
pubmed: 7 3 2020
medline: 6 3 2021
entrez: 7 3 2020
Statut: ppublish

Résumé

Advanced therapy medicinal products (ATMP) frequently lack of clinical data on efficacy to substantiate a future clinical use. This study aims to evaluate the efficacy to heal long bone delayed unions and non-unions, as secondary objective of the EudraCT 2011-005441-13 clinical trial, through clinical and radiological bone consolidation at 3, 6 and 12 months of follow-up, with subgroup analysis of affected bone, gender, tobacco use, and time since the original fracture. Twenty-eight patients were recruited and surgically treated with autologous bone marrow derived mesenchymal stromal cells expanded under Good Manufacturing Practices, combined to bioceramics in the surgical room before implantation. Mean age was 39 ± 13 years, 57% were males, and mean Body Mass Index 27 ± 7. Thirteen (46%) were active smokers. There were 11 femoral, 4 humeral, and 13 tibial non-unions. Initial fracture occurred at a mean ± SD of 27.9 ± 31.2 months before recruitment. Efficacy results were expressed by clinical consolidation (no or mild pain if values under 30 in VAS scale), and by radiological consolidation with a REBORNE score over 11/16 points (value of or above 0.6875). Means were statistically compared and mixed models for repeated measurements estimated the mean and confidence intervals (95%) of the REBORNE Bone Healing scale. Clinical and radiological consolidation were analyzed in the subgroups with Spearman correlation tests (adjusted by Bonferroni). Clinical consolidation was earlier confirmed, while radiological consolidation at 3 months was 25.0% (7/28 cases), at 6 months 67.8% (19/28 cases), and at 12 months, 92.8% (26/28 cases including the drop-out extrapolation of two failures). Bone biopsies confirmed bone formation surrounding the bioceramic granules. All locations showed similar consolidation, although this was delayed in tibial non-unions. No significant gender difference was found in 12-month consolidation (95% confidence). Higher consolidation scale values were seen in non-smoking patients at 6 (p = 0.012, t-test) and 12 months (p = 0.011, t-test). Longer time elapsed after the initial fracture did not preclude the occurrence of consolidation. Bone consolidation was efficaciously obtained with the studied expanded hBM-MSCs combined to biomaterials, by clinical and radiological evaluation, and confirmed by bone biopsies, with lower consolidation scores in smokers.

Sections du résumé

BACKGROUND AND STUDY AIM OBJECTIVE
Advanced therapy medicinal products (ATMP) frequently lack of clinical data on efficacy to substantiate a future clinical use. This study aims to evaluate the efficacy to heal long bone delayed unions and non-unions, as secondary objective of the EudraCT 2011-005441-13 clinical trial, through clinical and radiological bone consolidation at 3, 6 and 12 months of follow-up, with subgroup analysis of affected bone, gender, tobacco use, and time since the original fracture.
PATIENTS AND METHODS METHODS
Twenty-eight patients were recruited and surgically treated with autologous bone marrow derived mesenchymal stromal cells expanded under Good Manufacturing Practices, combined to bioceramics in the surgical room before implantation. Mean age was 39 ± 13 years, 57% were males, and mean Body Mass Index 27 ± 7. Thirteen (46%) were active smokers. There were 11 femoral, 4 humeral, and 13 tibial non-unions. Initial fracture occurred at a mean ± SD of 27.9 ± 31.2 months before recruitment. Efficacy results were expressed by clinical consolidation (no or mild pain if values under 30 in VAS scale), and by radiological consolidation with a REBORNE score over 11/16 points (value of or above 0.6875). Means were statistically compared and mixed models for repeated measurements estimated the mean and confidence intervals (95%) of the REBORNE Bone Healing scale. Clinical and radiological consolidation were analyzed in the subgroups with Spearman correlation tests (adjusted by Bonferroni).
RESULTS RESULTS
Clinical consolidation was earlier confirmed, while radiological consolidation at 3 months was 25.0% (7/28 cases), at 6 months 67.8% (19/28 cases), and at 12 months, 92.8% (26/28 cases including the drop-out extrapolation of two failures). Bone biopsies confirmed bone formation surrounding the bioceramic granules. All locations showed similar consolidation, although this was delayed in tibial non-unions. No significant gender difference was found in 12-month consolidation (95% confidence). Higher consolidation scale values were seen in non-smoking patients at 6 (p = 0.012, t-test) and 12 months (p = 0.011, t-test). Longer time elapsed after the initial fracture did not preclude the occurrence of consolidation.
CONCLUSION CONCLUSIONS
Bone consolidation was efficaciously obtained with the studied expanded hBM-MSCs combined to biomaterials, by clinical and radiological evaluation, and confirmed by bone biopsies, with lower consolidation scores in smokers.

Identifiants

pubmed: 32139130
pii: S0020-1383(20)30144-3
doi: 10.1016/j.injury.2020.02.070
pii:
doi:

Substances chimiques

Biocompatible Materials 0

Types de publication

Clinical Trial, Phase I Clinical Trial, Phase II Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

S63-S73

Informations de copyright

Copyright © 2020. Published by Elsevier Ltd.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors confirm that there are no known conflicts of interest associated with this publication and there has been no financial support for this work that could have influenced its outcome. The authors do not communicate any conflict of interest about this work and manuscript.

Auteurs

Enrique Gómez-Barrena (E)

Servicio de Cirugía Ortopédica y Traumatología, Hospital Universitario La Paz-IdiPAZ and Facultad de Medicina, Universidad Autónoma de Madrid, P° Castellana 261, 2804, Madrid, Spain. Electronic address: egomezb@salud.madrid.org.

Norma Padilla-Eguiluz (N)

Servicio de Cirugía Ortopédica y Traumatología, Hospital Universitario La Paz-IdiPAZ and Facultad de Medicina, Universidad Autónoma de Madrid, P° Castellana 261, 2804, Madrid, Spain.

Philippe Rosset (P)

Service de Chirurgie Orthopédique et Traumatologique 2, Hôpital Trousseau, Université François-Rabelais de Tours, CHU de Tours, Tours, France.

Florian Gebhard (F)

Department of Traumatology, Hand-, Plastic-, and Reconstructive Surgery, Center of Surgery, University of Ulm, Ulm, Germany.

Philippe Hernigou (P)

Orthopaedic Department, Hôpital Henri Mondor, InsermU955 and UPEC (University Paris-Est, Créteil), Créteil, France.

Nicola Baldini (N)

Laboratory for Orthopaedic Pathophysiology and Regenerative Medicine, Istituto Ortopedico Rizzoli, and Dept. of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy.

Helène Rouard (H)

Orthopaedic Department, Hôpital Henri Mondor, InsermU955 and UPEC (University Paris-Est, Créteil), Créteil, France; Établissement Français du Sang, Paris, France.

Luc Sensebé (L)

Établissement Français du Sang, Paris, France; STROMA Lab, UMR5273-INSERM U1031, Toulouse, France.

Rosa-María Gonzalo-Daganzo (RM)

Servicio de Hematología, Hospital Universitario Puerta de Hierro-Majadahonda, and Universidad Autónoma de Madrid, Madrid, Spain.

Rosaria Giordano (R)

Cell Factory, Center for Cellular Therapy and Cryobiology, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milano, Italy.

Eduardo García-Rey (E)

Servicio de Cirugía Ortopédica y Traumatología, Hospital Universitario La Paz-IdiPAZ and Facultad de Medicina, Universidad Autónoma de Madrid, P° Castellana 261, 2804, Madrid, Spain.

José Cordero-Ampuero (J)

Servicio de Cirugía Ortopédica y Traumatología, Hospital Universitario La Princesa and Facultad de Medicina, Universidad Autónoma de Madrid, Madrid, Spain.

Juan Carlos Rubio-Suárez (JC)

Servicio de Cirugía Ortopédica y Traumatología, Hospital Universitario La Paz-IdiPAZ and Facultad de Medicina, Universidad Autónoma de Madrid, P° Castellana 261, 2804, Madrid, Spain.

Marta Dominguez García-Simón (MD)

Servicio de Cirugía Ortopédica y Traumatología, Hospital Universitario La Paz-IdiPAZ and Facultad de Medicina, Universidad Autónoma de Madrid, P° Castellana 261, 2804, Madrid, Spain.

Julien Stanovici (J)

Service de Chirurgie Orthopédique et Traumatologique 2, Hôpital Trousseau, Université François-Rabelais de Tours, CHU de Tours, Tours, France.

Christian Ehrnthaller (C)

Department of Traumatology, Hand-, Plastic-, and Reconstructive Surgery, Center of Surgery, University of Ulm, Ulm, Germany.

Markus Huber-Lang (M)

Department of Traumatology, Hand-, Plastic-, and Reconstructive Surgery, Center of Surgery, University of Ulm, Ulm, Germany.

Charles Henri Flouzat-Lachaniette (CH)

Orthopaedic Department, Hôpital Henri Mondor, InsermU955 and UPEC (University Paris-Est, Créteil), Créteil, France.

Nathalie Chevallier (N)

Orthopaedic Department, Hôpital Henri Mondor, InsermU955 and UPEC (University Paris-Est, Créteil), Créteil, France; Établissement Français du Sang, Paris, France.

Davide Maria Donati (DM)

Laboratory for Orthopaedic Pathophysiology and Regenerative Medicine, Istituto Ortopedico Rizzoli, and Dept. of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy.

Benedetta Spazzoli (B)

Laboratory for Orthopaedic Pathophysiology and Regenerative Medicine, Istituto Ortopedico Rizzoli, and Dept. of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy.

Gabriela Ciapetti (G)

Laboratory for Orthopaedic Pathophysiology and Regenerative Medicine, Istituto Ortopedico Rizzoli, and Dept. of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy.

Sandrine Fleury (S)

Établissement Français du Sang, Paris, France; STROMA Lab, UMR5273-INSERM U1031, Toulouse, France.

Manuel-Nicolás Fernandez (MN)

Servicio de Hematología, Hospital Universitario Puerta de Hierro-Majadahonda, and Universidad Autónoma de Madrid, Madrid, Spain.

José-Rafael Cabrera (JR)

Servicio de Hematología, Hospital Universitario Puerta de Hierro-Majadahonda, and Universidad Autónoma de Madrid, Madrid, Spain.

Cristina Avendaño-Solá (C)

Servicio de Hematología, Hospital Universitario Puerta de Hierro-Majadahonda, and Universidad Autónoma de Madrid, Madrid, Spain.

Tiziana Montemurro (T)

Cell Factory, Center for Cellular Therapy and Cryobiology, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milano, Italy.

Carmen Panaitescu (C)

Victor Babes University of Medicine and Pharmacy, Timisoara, Romania.

Elena Veronesi (E)

Laboratory of Cellular Therapies, Department of Medical and Surgical Sciences for Children & Adults, University - Hospital of Modena and Reggio Emilia, Modena, Italy.

Markus Thomas Rojewski (MT)

Institut for Transfusion Medicine, Ulm University, and Institute for Clinical Transfusion Medicine and Immunogenetics Ulm, German Red Cross Blood Transfusion Service and University Hospital Ulm, Ulm, Germany.

Ramin Lotfi (R)

Institut for Transfusion Medicine, Ulm University, and Institute for Clinical Transfusion Medicine and Immunogenetics Ulm, German Red Cross Blood Transfusion Service and University Hospital Ulm, Ulm, Germany.

Massimo Dominici (M)

Laboratory of Cellular Therapies, Department of Medical and Surgical Sciences for Children & Adults, University - Hospital of Modena and Reggio Emilia, Modena, Italy.

Hubert Schrezenmeier (H)

Institut for Transfusion Medicine, Ulm University, and Institute for Clinical Transfusion Medicine and Immunogenetics Ulm, German Red Cross Blood Transfusion Service and University Hospital Ulm, Ulm, Germany.

Pierre Layrolle (P)

INSERM U957, Lab. Pathophysiology of bone resorption, Faculty of Medicine, University of Nantes, Nantes, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH